Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

617 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T. Reinisch W, et al. Among authors: geboes k. Gut. 2006 Aug;55(8):1138-44. doi: 10.1136/gut.2005.079434. Epub 2006 Feb 21. Gut. 2006. PMID: 16492717 Free PMC article. Clinical Trial.
Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis.
Joossens S, Colombel JF, Landers C, Poulain D, Geboes K, Bossuyt X, Targan S, Rutgeerts P, Reinisch W. Joossens S, et al. Among authors: geboes k. Gut. 2006 Nov;55(11):1667-9. doi: 10.1136/gut.2005.089623. Epub 2006 May 10. Gut. 2006. PMID: 16687433 Free PMC article. No abstract available.
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P, De Hertogh G, Lemaire K, Ferrante M, Schnitzler F, Thorrez L, Ma K, Song XY, Marano C, Van Assche G, Vermeire S, Geboes K, Schuit F, Baribaud F, Rutgeerts P. Arijs I, et al. Among authors: geboes k. Gut. 2009 Dec;58(12):1612-9. doi: 10.1136/gut.2009.178665. Epub 2009 Aug 20. Gut. 2009. PMID: 19700435 Free article. Clinical Trial.
Crohn's disease and pre-aphthoid lesions.
Rutgeerts P, Geboes K. Rutgeerts P, et al. Among authors: geboes k. Lancet. 1993 Jun 5;341(8858):1443-4. doi: 10.1016/0140-6736(93)90886-l. Lancet. 1993. PMID: 8099145 No abstract available.
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease.
Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P. Cornillie F, et al. Among authors: geboes k. Aliment Pharmacol Ther. 2001 Apr;15(4):463-73. doi: 10.1046/j.1365-2036.2001.00956.x. Aliment Pharmacol Ther. 2001. PMID: 11284774 Free article. Clinical Trial.
617 results